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Diagnostic and treatment tools for HIV are well known
and are widely available today. Equitable accessibility to
these tools is a major area of concern. The WHO estimates
that about 7 M persons are in need of ARV therapy in low
and middle-income countries around the world. The
WHO "3 × 5" initiative, launched in 2003, intended to
have brought ARV treatment to at least 3 M persons by the
end of 2005. By June 2005, only about 970,000 persons
in low and middle-income countries were receiving ARV
treatment. Latin America and the Caribbean lead the way
with about 62% of those I need receiving ARV treatment.
North Africa and the Middle East (5%) and Sub-Sahara
Africa (11%) showed the lowest accessibility.
Before 2001, very few low and middle-income countries
had an ARV-based treatment program. Brazil had started
local production of ARVs, ignoring patents owned by the
large multinational R&D pharmaceutical giants. This
move enabled Brazil to provide universal treatment to
PLWHA. Other Latin American countries developed ARV-
based treatment programs by 2000 also. These countries
included Argentina and Mexico. In the Caribbean, the
Bahamas, Barbados, Jamaica and Trinidad and Tobago,
mainly through World Bank loans initiated ARV-based
treatment programs, although at highly unsustainable
cost. Indian pharmaceutical companies, such as CIPLA
and Ranbaxy began the generic production of a number of
ARVs, including the combination cocktail of LSN and
these cheaper versions of the ARVs were made available to
many African countries. Thus, by 2001, albeit at a pain-
fully slow and glacial pace, access begun to improve in
low and middle-income countries. Today, massive injec-
tion of funds have began to flow and generic version of
the ARVs are far more accessible, yet overall, less than 20%
of PLWHA in low and middle-income countries have
access to ARV-based treatment.
One resource-poor country that is changing the poor
access to ARVs is Guyana, one of the poorest Caribbean
countries. In 2004, the World Development Report
ranked Guyana, in terms of the HDI, at 103. Guyana is a
HIPC country. Guyana has an HIV prevalence of between
3.5 to 5.5%. It is estimated that about 3,000 persons are
in need of ARVs. By 2001, no formal ARV-based treatment
program existed. Today, approximately 1,000 persons are
on ARV treatment program. Guyana benefits from fund-
ing through the Global Fund, the World Bank and is one
of the PEPFAR countries. There are also technical assist-
ance through CIDA, PAHO/WHO and UNICEF.
Guyana also has offered universal treatment, including
ARVs and laboratory testing for CD4 to everyone living
with HIV and who reaches the criteria established for the
initiation of treatment. However, roll out to reach every-
one who needs to be on ARV treatment has been slow due
to constraints of capacity. Still, the treatment program is
considered to be one of the success stories in the fight
against HIV/AIDS. Thus, far, the ARVs used in the treat-
ment of HIV/AIDS patients have been generic ARVs pro-
duced by a local company, the New GPC. There are 15
locally produced formulations and combination therapy
with LSN can be obtained at a cost of $US140 per patient
annually.
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